Priyank Kumar, PhD, MS
Assistant Professor, Head of Laboratory Research, Pharmaceutical and Biomedical Sciences
“You cannot teach a man anything; you can only help him discover it in himself”-Galileo
My academic and research training has provided me with a comprehensive and diverse background in a wide variety of scientific disciplines including clinical pharmacology, cancer biology, psychopharmacology, pharmaceutical compounding and calculations. These distinct experiences have contributed to my overall desire to pursue my career as a scientist. The possibility of improving therapy for patients combined with the intellectual challenge of fundamental research fueled my passion for research.
PhD, St. John’s University, NY; 2014
MS, St John’s University, NY; 2008
B. Pharm, Rajeev Academy of Pharmacy, Mathura, India; 2003
- Pharmaceutical Compounding
- Pharmacology with research expertise in cancer and opioid pharmacology
- Multidrug Resistance
- Data Science and Informatics
The focus of our laboratory is to carry out research at the crossroad of pharmacology, biology and medicine to develop novel platforms for understanding biological pathways and finding treatments for human diseases. Our long-term goals are to improve therapies for diseases associated with multi drug resistance (MDR), develop physiologic and mechanism-based disease models, utilize systems pharmacology as a tool to delineate causal pathways to adverse events and facilitate the identification of biomarkers associated with pain and oncology.
- Adherence to ART and cancer chemotherapy in HIV and cancer respectively (Ongoing collaborative project)
- Impact of opioid receptor polymorphism in pain management (Ongoing collaborative project)
- ABC transporters mediated MDR related to anticancer drugs
- Role of genes regulating the onset of Autophagy in tumor microenvironment
- Research in Education
- Regulatory Research
Academic and Professional Honors
Faculty Research Award, Touro College of Pharmacy, NY, (2014-2015)
- “Role of ABC transporters in cancer chemotherapeutics”. Department of Pharmacology, New York Medical College, NY (Feb 2015)
Editorial Board Member/Reviewer
Editor: Journal of Pharmacology and Toxicology Research, ScienceScript LLC.
Editorial Board Member: Biochemistry and Analytical Biochemistry, Omics Publishing Group, American Journal of Medical Sciences and Medicine, Science and Education Publishing.
External clinical reviewer: The Lancet; The Lancet Diabetes and Endocrinology, Infectious Disease, Neurology, Oncology, Psychiatry and Respiratory Medicine, Elsevier Publishing
- International Immunopharmacology; Elsevier Publishing
- Environmental Toxicology and Pharmacology; Elsevier Publishing
- Public Health; Manuscript review in public health related issues, Elsevier Publishing
- International Journal of Educational Development; Elsevier Publishing
- Educational Research Review; Elsevier Publishing
- International Immunopharmacology; Elsevier Publishing
- SOJ Pharmacy and Pharmaceutical Sciences; Symbiosis Online Publishing
- American Journal of Pharmaceutical Education; American Association of Colleges of Pharmacy
- Journal of Pharmaceutical Sciences and Pharmacology; American Scientific Publishers
- American Journal of Pharmacological Sciences; Science and Education Publishing
- American Journal of Medical Sciences and Medicine; Science and Education Publishing
- Immune Cell; Vedic Research Inc
- VRI Phytomedicine; Vedic Research Inc
- Journal of Medicinal Chemistry Communications; Royal Society of Chemistry
- Active member of NYS Board Task force
- Active member of Curriculum Committee
- Active member of Curriculum Mapping Task Force
- Chair of Academic standing and Awards committee
- Course Coordinator for Pharmacology
- Course Coordinator for Pharmaceutical compounding
- Course Coordinator for Pharmaceutical Calculations
- Course Co-Coordinator for Clinical Oncology
- Course Co-Coordinator for Pharmacommetrics
- Faculty Advisor of Kappa Psi
- Research Student’s Mentor
- Lab Safety Coordinator
- Vice Chair, Faculty Council
- Volunteer teacher, St. Johns University, NY (2013-2014): Afterschool STEM Mentoring Program, NYAS
- Judge, Long Island Science and Engineering Fair (LISEF) (2015)
- New York Academy of Sciences (NYAS)
- American Association of Advancement of Science (AAAS)
- American Association for Cancer Research (AACR)
- American Society for Clinical Pharmacology and Therapeutics (ASCPT)
- International Society of Pharmacometrics (ISoP)
- American Society of Clinical Oncologist (ASCO)
- American Association of College of Pharmacy (AACP)
- Clinical Oncology
- Research Methods/Laboratory Techniques in Cancer Pharmacology
- NYS Boards Review Course
- Independent Research
- Pharmaceutical Biotechnology
- Rumore, M. M., Assefa, H., Basu, P., Kumar, P., Patel, Y., Venjara, S. March 27-30, 2016. Analysis of MedWatch Alerts 2009-2015. American Pharmacists Association Annual Meeting. Baltimore, MD
- Anreddy, N; Patel, A; Zhang, Y.K; Wang, Y.J; Shukla, S; Kathawala, R.J; Kumar, P; Gupta, P; Ambudkar, S.V; Wurpel, J.N.D; Chen, Z.S; Guo, H. 2015. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. Proceedings: AACR 106th Annual Meeting; April 18-22, 2015; Philadelphia, PA
- Rumore, M. M., Assefa, H., Basu, P., Kumar, P., Patel, Y. March 27-30, 2015. Analysis of MedWatch Alerts 2009-2014. American Pharmacists Association Annual Meeting. San Diego, CA
- Kumar, P., Kathawala, R. J., Zhang, H., Anreddy, N., Chen, Y., Gupta, K., Trombetta, L. D., Chen, Z. S., 2013. Quizartinib (AC220) potentiates the antineoplastic activity of wild type ABCG2 and ABCB1 substrates. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting, Boston.
- Wang, D. S., Patel, A., Kumar, P., Xu, R. H., Chen, Z. S. 2013. ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting, Boston.
- Sun, Y., Chen, J., Deng, W., Xiao, Z., Kathawala, R., Kumar, P., Sodani, K., Chen, S. D., Jiang, W., Chen, Z. S., 2011. XR9576 (tariquidar) is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance. 8th Annual North American ABC Genetic Workshop, NCI-Fredrick Maryland.
- Kumar, P., Sirohi, S., Dighe, S. V., Yoburn, B. C., 2008. Hydromorphone efficacy and treatment protocol impact on tolerance and μ-opioid receptor regulation. Society for Neuroscience Annual Meeting, Washington D.C.
- Kumar, P., Sirohi, S., Yoburn, B. C., 2007. Opioid agonist efficacy and regulation of trafficking and signaling proteins. ASPET Annual Meeting, Washington D.C.
- Yoburn, B. C., Sunkarneni, S., Sirohi, S., Kumar, P., Walker, E. A., 2007. Tolerance, receptor regulation and efficacy of hydromorphone. ASPET Annual Meeting, Washington D.C.
- Pawar, M., Zhang, Q., Kumar, P., Yoburn, B. C., 2005. Oxycodone-induced tolerance does not require µ-opioid receptor regulation. Society for Neuroscience Annual Meeting, Washington D.C.
- Kumar, P., Basu, P., Knapp, K. K. 2015. Overview of Ebola Outbreak Stresses Proactive Solutions. Medscape. Article ID 846871
- Anreddy, N; Patel, A; Zhang, Y.K; Wang, Y.J; Shukla, S; Kathawala, R.J; Kumar, P; Gupta, P; Ambudkar, S.V; Wurpel, J.N.D; Chen, Z.S; Guo, H. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. Oncotarget. In Press
- Kumar, P. 2015. Malnutrition in India. IPROVOK
- Akhtar, A., Befkadu, E., Basu, P., Kumar, P. 2014. Exposing the Origins of the Ebola Outbreak: Urging for a Shift in Response from Reactive to Proactive. Am. J. IDM. 2(6A), 1-18
- Sun, Y. L., Kumar, P., Sodani, K., Patel, A., Pan, Y., Baer, M. R., Chen, Z. S., W. Q, J. 2014. Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncol. Rep. [Epub ahead of print].
- Sodani, K., Patel, A., Anreddy, N., Singh, S., Yang, D. H., Kathawala, R. J., Kumar, P., Talele, T. T., Chen, Z. S. 2014. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem. Pharm. [in press].
- Wang, Y. J., Kathawala, R. J., Zhang, Y. K., Patel, A., Kumar, P., Shukla, S., Fung, K. L., Ambudkar, S. V., Talele, T. T., Chen, Z. S., 2014. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochem. Pharmacol. In Press.
- H, X. C., Kumar, P., A, Nagaraju., Xiao, X., Yang, D. H. and Chen, Z. S., 2014. P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae. Handbook of anticancer drugs from marine origin. Springer. In Press
- Sun, Y. L., Chen, J. J., Kumar, P., Chen, K., Sodani, K., Patel, A., Chen, Y. L., Chen, S. D., Jiang, W. Q., Chen, Z. S. 2013. Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar. PLoS One. 8(2), e55576.
- Kumar, P., Zhang, D. M., Degenhardt, K., Chen, Z. S., 2012. Autophagy and transporter based multi drug resistance. Cells. 1(3), 558-575.
- Sun, Y. L., Patel, A., Kumar, P., Chen, Z. S., 2012. Role of ABC transporters in cancer chemotherapy. Chin. J. Cancer. 31(2), 51-7.
- Kumar, P., Sunkarneni, S., Sirohi, S., Dighe, S. V., Walker, E. A., Yoburn, B. C., 2008. Hydromorphone efficacy and treatment protocol impact on tolerance and μ-opioid receptor regulation. Eur. J. Pharm. 597, 39-45.
- Sirohi, S., Kumar, P., Yoburn, B. C., 2007. µ-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy. J. Pharm. Exp. Ther. 323, 701-707.
- Pawar, M., Kumar, P., Sunkaraneni, S., Sirohi, S., Walker, E. A., Yoburn, B. C., 2007. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of μ-opioid receptors and dynamin-2. Eur. J. Pharm. 563, 92-101.
- Huang, X., Kumar, P., Anreddy, N., Xiao, X., Yang, D. H., Chen, Z.S. 2015. P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae. Handbook of Anticancer Drugs from Marine Origin 1, 593-619
Interests/Hobbies/Life Outside of Work
Skiing and other Adventure Sports, Cooking and Traveling